Lakefront Biotherapeutics American Depositary Shares
LKFT
78 hedge funds and large institutions have $960M invested in Lakefront Biotherapeutics American Depositary Shares in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 21 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
56% more capital inflows, than outflows
Capital inflows: $58.8M | Capital outflows: $37.6M
1.29% more ownership
Funds ownership: 47.44% → 48.73% (+1.3%)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
13% less funds holding
Funds holding: 90 → 78 (-12)
52% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Madison Avenue Partners
New York
|
+$27.9M |
| 2 |
Prosight Management
Dallas,
Texas
|
+$14M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.93M |
| 4 |
Renaissance Technologies
New York
|
+$2.62M |
| 5 |
Millennium Management
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Segall Bryant & Hamill
Chicago,
Illinois
|
-$12.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.33M |
| 3 |
Old Mission Capital
Chicago,
Illinois
|
-$2.87M |
| 4 |
Man Group
London,
United Kingdom
|
-$2.41M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.32M |
LKFT Hedge Fund Activity: Q2 2026 in Review
78 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2026, worth a combined $960M — up 2.4% from $938M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of LKFT and 10 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 26 added.
The largest buyer was Madison Avenue Partners, adding an estimated $27.9M. The largest seller was Segall Bryant & Hamill, exiting entirely with an estimated $12.8M sold.
- 78 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2026, down from 90 in Q1 2026.
- Funds reported $960M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2026, up 2.4% quarter-over-quarter.
- 10 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2026 and 21 closed out, a net change of -11 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2026 was Madison Avenue Partners, an estimated $27.9M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2026 was Segall Bryant & Hamill, an estimated $12.8M sold.
Based on aggregated 13F filings for Q2 2026.